Study finds there is little evidence to suggest that an oxycodone HCI extended-release tablets nonformulary restriction has a direct effect on patient enrollment behavior.
Formulary restrictions are used by health plans to control cost and encourage quality and safety of the necessary prescription utilization. Although there are Medicare payers that think certain agents, like branded oxycodone HCI extended-release tablets (OERs), are on their formularies to attract high-cost members to join the plan, there is little evidence to suggest that an OER nonformulary restriction has a direct effect on patient enrollment behavior.
A study recently published in Journal of Managed Care and Specialty Pharmacy utilized IMS pharmacy and medical claims data from July 1, 2011, to December 31, 2014, to assess the disenrollment rates, patient migration, and healthcare costs among OER users who disenrolled from a national Medicare Advantage Prescription Drug plan (study-MAPD) in the year following OER nonformulary restriction. The study participants were from study-MAPD, at least 18 years old, were chronic OER users with 2 or more OER claims 6 months prior to the nonformulary restriction data, and had continuous activity in pharmacy and medical claims for 6 months before and after the index.
The researchers used 2012 and 2014 pre-restriction/post-restriction as comparison years. All of the groups were then followed up for 6 months after the index, as the year-to-year disenrollment rates of OER patients, the overall plan, costs, and patient characteristics of those who disenrolled were calculated.
On January 1, 2013, a total of eligible 2935 OER users were identified from the study-MAPD population following the nonformulary restrictions on OERs. For the comparison years, in 2012 (pre-restriction) 2245 patients were identified, and in 2014 (post-restriction), 2222 OER patients were identified. Although patient characteristics were similar among the patient groups during the 3 study years, the disenrollment rates of OER uses varied from 12.9% in 2012, 5.55% in 2013, and 14.3% in 2014, while the disenrollment rates for the overall plan were 18.3% in 2012, 7.6% in 2013, and 14.1% in 2014.
“Approximately 40% of OER users who disenrolled from the study-MAPD migrated to plans also imposing a nonformulary restriction on OERs, while about 25% moved to plans with less restrictive OER coverage,” the authors found. “The majority (59.9%) of patients continued OER use irrespective of their disenrollment from the study-MAPD in 2013.”
As for cost, the decrease in per patient per month (PPPM) cost was not significant, $117, among OER patients post-restriction, while the difference-in-difference analysis demonstrated a net post-restriction increase of $124.
“This analysis indicated that, compared with the overall study-MAPD, disproportionate migration with other plans of chronic OER users was not observed after an OER nonformulary restriction was implemented, and no evidence supported the assumption that imposing an OER nonformulary restriction would lead to more severe and/or more costly patients leaving the plan,” the authors concluded.
Although there is minimal evidence demonstrating that OER nonformulary restriction has an effect on patient enrollment behavior or contribute to higher disenrollment, additional studies are needed to analyze the increases in pharmacy and medical costs before and after the OER restriction in nonopioid users to assess its influence in the results.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More
President Biden will preview his plan to more than double the size of Medicare’s new drug price negotiation program in the upcoming State of the Union address; Mexicans and Central Americans were most affected by the pandemic in terms of all-cause mortality; two Alabama fertility clinics said they expect to resume in vitro fertilization (IVF) services after a bill was passed to protect doctors.
Read More